April K.S. Salama

Duke Cancer Institute ORCID: 0000-0002-8105-5374

1

h-index

1

Publications

1,528

Citations

Publications

1 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Frequent Co-Authors

Antoni Ribas

Parker Institute for Cancer Immunotherapy

Igor Puzanov

American Society of Clinical Oncology

Reinhard Dummer

Dirk Schadendorf

Deutschen Konsortium für Translationale Krebsforschung

Omid Hamid

Angeles Clinic and Research Institute

Caroline Robert

Institut Gustave Roussy

Researcher Info

h-index: 1
Publications: 1
Citations: 1,528
Institution: Duke Cancer Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8105-5374

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.